ARCHIMED Diagnostics, along with minority investor La Caisse, acquires Stago a global leader in blood coagulation analysis

Working with Stago management, ARCHIMED aims to expand sales and profits by building on gold-standard products in both developed and developing nations.

ARCHIMED Diagnostics – the Diagnostics team of global private equity healthcare specialist ARCHIMED – has purchased alongside global investment group La Caisse (formerly CDPQ), Stago, a world leader for the analysis of blood coagulation issues (hemostasis).  Stago develops and manufactures hemostasis equipment and reagents. It has unique expertise and a track record of innovation in this specialty.

Stago is held through ARCHIMED’s MED Platform II fund and was purchased from the founding Viret family by the Diagnostics team through an unspecified mix of equity and unitranche debt. Stago sells its products in 115 countries and posted revenues of €550 million in 2025.  Based in Asnières-sur-Seine (greater Paris), Stago was founded in 1945 and is the only pure-play hemostasis analysis company in the world. Stago’s leadership team is taking a minority stake as part of the deal.

“In addition to financial muscle, ARCHIMED and La Caisse have the operational sophistication and discretion to help us grow at a pivotal moment in our company’s history,” says incumbent Stago CEO Jean-Claude Piel, who retires from his post, becoming Chief of the Scientific and Technology Monitoring Committee. “ARCHIMED’s diagnostics expertise is key for accelerating the efficient rollout of a major, new generation of Stago products,” says Philippe Barroux, Stago’s CEO-elect. Barroux, a 38-year Stago veteran, is currently CEO of operations in North America and China. “This partnership is all about reigniting innovation at Stago.”

 

“Stago is a recognized leader in blood coagulation analysis, operating in a segment we know well, and serving a mission-critical role in medical diagnostics. Our investment alongside ARCHIMED reflects the value we place on partnerships and businesses with strong fundamentals,” says Martin Longchamps, Executive Vice-President and Head of Private Equity and Private Credit at La Caisse.

Working closely with Stago management, ARCHIMED will deploy its MedValue template – ARCHIMED’s levers for accelerating the growth of partnering companies via internationalization (often including bolt-on acquisitions), innovation and product range expansion.

Diagnostics is a primary investment sector for ARCHIMED, and one of the seven major sectors mapped through ARCHIMED’s MedSeg, its proprietary sector analysis tool covering 430 sub-segments of the global health industry. For the acquisition of Stago, ARCHIMED also deployed MedDiscover, a proprietary set of tools and processes permitting ARCHIMED to identify and effectively engage with leading companies operating in ARCHIMED’s prioritized sub-sectors.

Stago is MED Platform II’s 10^th investment. All of MED Platform II’s investments have been first-time leveraged buyouts for the companies acquired. MED Platform II, more than two times oversubscribed, closed on €3.5 billion in June, 2023. According to Preqin data, the fund is a top quartile performer for its vintage year as are all ARCHIMED funds. After the Stago transaction, MED Platform II is some 70 percent invested.